OBJECTIVE: To investigate the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA BNT162b2 vaccine on women's menstrual cycle. METHODS: In this questionnaire-based cross-sectional study, we assessed menstrual pattern and changes in women who completed the SARS-CoV-2 mRNA BNT162b2 vaccine 3 months before and after receiving the vaccine. Included were women aged 18-50 years without known gynecologic comorbidities who regularly monitor their menstruation through electronic calendars. All participants competed a detailed questionnaire on their menstrual symptoms including information on any irregular bleeding. To minimize bias, each woman served as a self-control before and after vaccination. Primary outcome was rate of irregular bleeding following vaccination and secondary outcome was presence of any menstrual change, including irregular bleeding, mood changes, or dysmenorrhea following the vaccine. RESULTS: A total of 219 women met the inclusion critieria. Of them, 51 (23.3%) experienced irregular bleeding following the vaccine. Almost 40% (n = 83) of study participants reported any menstrual change following vaccination. Parity was positively asssociated with irregular bleeding with 26 (50%) of those suffering from irregular bleeding being multiparous compared with only 53 (31.5%) of women with no irregular bleeding (nulliparous 46% vs 60%, multiparous 50% vs 31%, rest 4% vs 8%, P = 0.049). The presence of medical comorbidities was also significantly higher among patients who experienced irregular bleeding (20.0% vs 6.0%, P = 0.003). CONCLUSION: Our study shows relatively high rates of irregular bleeding and menstrual changes after receiving the SARS-CoV-2 mRNA BNT162b2 vaccine. Further research is needed to confirm our findings and to better characterize the magnitude of change and any possible long-term implications.
OBJECTIVE: To investigate the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA BNT162b2 vaccine on women's menstrual cycle. METHODS: In this questionnaire-based cross-sectional study, we assessed menstrual pattern and changes in women who completed the SARS-CoV-2 mRNA BNT162b2 vaccine 3 months before and after receiving the vaccine. Included were women aged 18-50 years without known gynecologic comorbidities who regularly monitor their menstruation through electronic calendars. All participants competed a detailed questionnaire on their menstrual symptoms including information on any irregular bleeding. To minimize bias, each woman served as a self-control before and after vaccination. Primary outcome was rate of irregular bleeding following vaccination and secondary outcome was presence of any menstrual change, including irregular bleeding, mood changes, or dysmenorrhea following the vaccine. RESULTS: A total of 219 women met the inclusion critieria. Of them, 51 (23.3%) experienced irregular bleeding following the vaccine. Almost 40% (n = 83) of study participants reported any menstrual change following vaccination. Parity was positively asssociated with irregular bleeding with 26 (50%) of those suffering from irregular bleeding being multiparous compared with only 53 (31.5%) of women with no irregular bleeding (nulliparous 46% vs 60%, multiparous 50% vs 31%, rest 4% vs 8%, P = 0.049). The presence of medical comorbidities was also significantly higher among patients who experienced irregular bleeding (20.0% vs 6.0%, P = 0.003). CONCLUSION: Our study shows relatively high rates of irregular bleeding and menstrual changes after receiving the SARS-CoV-2 mRNA BNT162b2 vaccine. Further research is needed to confirm our findings and to better characterize the magnitude of change and any possible long-term implications.
Authors: Seyed M Moghadas; Thomas N Vilches; Kevin Zhang; Chad R Wells; Affan Shoukat; Burton H Singer; Lauren Ancel Meyers; Kathleen M Neuzil; Joanne M Langley; Meagan C Fitzpatrick; Alison P Galvani Journal: Clin Infect Dis Date: 2021-12-16 Impact factor: 9.079
Authors: Naama Lessans; Amihai Rottenstreich; Shira Stern; Adi Gilan; Tal D Saar; Shay Porat; Uri P Dior Journal: Int J Gynaecol Obstet Date: 2022-07-20 Impact factor: 4.447
Authors: Mark J Mulligan; Kirsten E Lyke; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; Kathleen Neuzil; Vanessa Raabe; Ruth Bailey; Kena A Swanson; Ping Li; Kenneth Koury; Warren Kalina; David Cooper; Camila Fontes-Garfias; Pei-Yong Shi; Özlem Türeci; Kristin R Tompkins; Edward E Walsh; Robert Frenck; Ann R Falsey; Philip R Dormitzer; William C Gruber; Uğur Şahin; Kathrin U Jansen Journal: Nature Date: 2020-08-12 Impact factor: 69.504
Authors: Kawsar R Talaat; Neal A Halsey; Amber B Cox; Christian L Coles; Anna P Durbin; Amritha Ramakrishnan; Jay H Bream Journal: Influenza Other Respir Viruses Date: 2018-01-04 Impact factor: 4.380
Authors: Cristina Menni; Kerstin Klaser; Anna May; Lorenzo Polidori; Joan Capdevila; Panayiotis Louca; Carole H Sudre; Long H Nguyen; David A Drew; Jordi Merino; Christina Hu; Somesh Selvachandran; Michela Antonelli; Benjamin Murray; Liane S Canas; Erika Molteni; Mark S Graham; Marc Modat; Amit D Joshi; Massimo Mangino; Alexander Hammers; Anna L Goodman; Andrew T Chan; Jonathan Wolf; Claire J Steves; Ana M Valdes; Sebastien Ourselin; Tim D Spector Journal: Lancet Infect Dis Date: 2021-04-27 Impact factor: 25.071
Authors: Naama Lessans; Amihai Rottenstreich; Shira Stern; Adi Gilan; Tal D Saar; Shay Porat; Uri P Dior Journal: Int J Gynaecol Obstet Date: 2022-07-20 Impact factor: 4.447